P35 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
p35 (also known as CDK5R1) is the neuronal-specific regulatory subunit of cyclin-dependent kinase 5 (CDK5). It plays a critical role in brain development, synaptic plasticity, and neuronal function. The p35/CDK5 complex is essential for proper neuronal migration, axon guidance, and synapse formation during development and throughout life .
| Property |
Value |
| Protein Name |
p35 / CDK5R1 |
| Gene |
CDK5R1 |
| UniProt ID |
Q15078 |
| Molecular Weight |
~35 kDa (350 amino acids) |
| Isoforms |
p35 (full-length), p25 (cleaved form) |
| Tissue Specificity |
Neuron-specific |
The p35 protein contains several key structural features:
- N-terminal myristoylation site — enables membrane association and localization
- CDK5 binding domain — mediates interaction with CDK5 to form the active kinase complex
- p10 cleavage site — calpain-mediated cleavage generates the p10 subunit
- p25 cleavage product — pathological cleavage generates p25 in disease states
During embryonic and early postnatal development, p35/CDK5 regulates:
- Neuronal migration — Controls radial migration of cortical neurons
- Axon guidance — Regulates axonal outgrowth and pathfinding
- Synaptogenesis — Essential for proper synapse formation and maturation
- Cytoskeletal dynamics — Phosphorylates tau, MAP1B, and neurofilament proteins
In mature neurons, p35/CDK5 activity modulates:
- Long-term potentiation (LTP) — Regulates AMPA receptor trafficking
- Long-term depression (LTD) — Controls NMDA receptor signaling
- Learning and memory — Essential for hippocampal synaptic plasticity
- Dendritic spine morphology — Maintains spine stability and density
In Alzheimer's disease, p35 is cleaved by calpain to generate p25, a truncated form that:
- Lacks the membrane targeting domain
- Accumulates in the cytoplasm
- Leads to constitutive CDK5 activation
- Causes hyperphosphorylation of tau
- Promotes neurofibrillary tangle formation
The p25/CDK5 complex is hyperactive in AD brains and contributes to:
- Tau pathology and NFT formation
- Synaptic dysfunction and loss
- Neuronal death
- Cognitive decline
Dysregulation of p35/CDK5 signaling in PD:
- Contributes to dopaminergic neuron degeneration
- Phosphorylates alpha-synuclein, promoting aggregation
- Interacts with parkin and PINK1 pathways
- Regulates mitochondrial dysfunction
In ALS:
- CDK5/p35 activity regulates motor neuron survival
- TDP-43 pathology involves CDK5-mediated phosphorylation
- Disrupted cytoskeletal dynamics in motor neurons
Targeting the p35/CDK5 pathway for neurodegeneration:
- CDK5 inhibitors — Various compounds in development
- Calpain inhibitors — Prevent p35 to p25 cleavage
- p25-targeted antibodies — Immunotherapy approaches
- Gene therapy — Modulating CDK5R1 expression
- CDK5 is essential for viability, making complete inhibition toxic
- Timing of intervention is critical (development vs. disease)
- Blood-brain barrier penetration for drug delivery
CDK5R1 is predominantly expressed in:
- Cerebral cortex — Highest expression in layers II-VI
- Hippocampus — CA1-CA3 regions, dentate gyrus
- Cerebellum — Purkinje cells
- Basal ganglia — Striatum, substantia nigra
- Brainstem — Various nuclei
Expression is neuron-specific and peaks during development.
Key partners of p35/CDK5:
- CDK5 — Kinase partner, forms active complex
- p35 — Can form homodimers
- Filamin A — Scaffold for signaling complexes
- CASK — Synaptic scaffold protein
- N PAS — Potential co-activator
The study of P35 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.